Compare Stocks: OKUR, AVTE, EIKN, and PRTA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$14.71 -12.2%	$20.43	$89.95 ▼ $99.05	$426.37M	0.95	53,591 shs	1.46 million shs
EIKN Eikon Therapeutics	$7.96 -2.2%	$10.07	$7.72 ▼ $17.40	$429.80M	N/A	413,906 shs	74,154 shs
OKUR OnKure Therapeutics	$3.00 +1.9%	$3.75	$2.23 ▼ $5.38	$120.22M	0.23	241,550 shs	10,559 shs
PRTA Prothena	$8.64 -0.5%	$8.92	$7.73 ▼ $11.80	$452.20M	-0.33	503,476 shs	62,204 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+0.12%	-3.57%	-21.46%	-23.47%	+111.62%
EIKN Eikon Therapeutics	-9.47%	-4.47%	-27.15%	-17.46%	+812,999,900.00%
OKUR OnKure Therapeutics	-5.16%	+2.08%	-24.42%	-30.33%	+16.21%
PRTA Prothena	-3.45%	+5.34%	-7.56%	-6.36%	+4.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$14.71 -12.2%	$20.43	$89.95 ▼ $99.05	$426.37M	0.95	53,591 shs	1.46 million shs
EIKN Eikon Therapeutics	$7.96 -2.2%	$10.07	$7.72 ▼ $17.40	$429.80M	N/A	413,906 shs	74,154 shs
OKUR OnKure Therapeutics	$3.00 +1.9%	$3.75	$2.23 ▼ $5.38	$120.22M	0.23	241,550 shs	10,559 shs
PRTA Prothena	$8.64 -0.5%	$8.92	$7.73 ▼ $11.80	$452.20M	-0.33	503,476 shs	62,204 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+0.12%	-3.57%	-21.46%	-23.47%	+111.62%
EIKN Eikon Therapeutics	-9.47%	-4.47%	-27.15%	-17.46%	+812,999,900.00%
OKUR OnKure Therapeutics	-5.16%	+2.08%	-24.42%	-30.33%	+16.21%
PRTA Prothena	-3.45%	+5.34%	-7.56%	-6.36%	+4.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
EIKN Eikon Therapeutics	2.50	Moderate Buy	$25.00	214.27% Upside
OKUR OnKure Therapeutics	2.25	Hold	$17.50	484.11% Upside
PRTA Prothena	2.75	Moderate Buy	$24.57	184.42% Upside

Current Analyst Ratings Breakdown

Latest OKUR, AVTE, EIKN, and PRTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	OKUR OnKure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/7/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	EIKN Eikon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/14/2026	OKUR OnKure Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$14.00
8/14/2026	EIKN Eikon Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$5.00 ➝ $4.00
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	EIKN Eikon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/28/2026	OKUR OnKure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
PRTA Prothena	$9.68M	46.72	N/A	N/A	$5.21 per share	1.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	-$59.52M	-$3.50	N/A	N/A	N/A	N/A	-49.01%	-45.77%	11/5/2026 (Estimated)
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	3.17	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)

Latest OKUR, AVTE, EIKN, and PRTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million
8/4/2026	Q2 2026	OKUR OnKure Therapeutics	-$0.5350	-$0.31	+$0.2250	-$0.31	$0.17 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
EIKN Eikon Therapeutics	N/A	9.89	9.89
OKUR OnKure Therapeutics	N/A	26.75	26.75
PRTA Prothena	N/A	25.05	25.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
EIKN Eikon Therapeutics	N/A
OKUR OnKure Therapeutics	90.98%
PRTA Prothena	97.08%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
EIKN Eikon Therapeutics	N/A
OKUR OnKure Therapeutics	2.17%
PRTA Prothena	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A
OKUR OnKure Therapeutics	45	40.40 million	39.52 million	N/A
PRTA Prothena	67	52.35 million	46.91 million	Optionable

OKUR, AVTE, EIKN, and PRTA Headlines

Recent News About These Companies

William Scully Acquires 100,000 Shares of Prothena (NASDAQ:PRTA) Stock

September 23 at 4:23 AM | americanbankingnews.com

Prothena stock falls to USD 8.51 as earnings beat estimates

September 22 at 6:39 PM | ad-hoc-news.deA

Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 100,000 Shares

September 22 at 4:22 AM | insidertrades.com

Prothena Corp Public Ltd Insider Bought Shares Worth $843,460, According to a Recent SEC Filing

September 21 at 11:14 PM | marketscreener.comM

William Scully Buys 100,000 Shares of Prothena (NASDAQ:PRTA) Stock

September 21 at 5:07 PM | marketbeat.com

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

September 21 at 1:40 PM | zacks.com

[PRTA] Attention!! Reaching the 'Previous Buy Price' of Big Players Who Sold at the Top! Prothena Dip-Buying Strategy Targeting Chart Pivot Points

September 18, 2026 | note.comN

Prothena Corporation plc (NASDAQ:PRTA) Receives Average Recommendation of "Moderate Buy" from Analysts

September 18, 2026 | marketbeat.com

Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026 | businesswire.com

Prothena (NASDAQ:PRTA) Major Shareholder Purchases 27,000 Shares of Stock

September 4, 2026 | insidertrades.com

Prothena (NASDAQ:PRTA) Major Shareholder Purchases $255,690.00 in Stock

September 3, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Share Price Passes Below Two Hundred Day Moving Average - What's Next?

September 1, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 50,000 Shares

August 22, 2026 | insidertrades.com

KMDA or PRTA: Which Is the Better Value Stock Right Now?

August 14, 2026 | zacks.com

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

August 8, 2026 | theglobeandmail.com

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

August 7, 2026 | zacks.com

Prothena: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

August 6, 2026 | businesswire.com

Prothena (NASDAQ:PRTA) Insider Sells $64,897.14 in Stock

July 31, 2026 | insidertrades.com

Prothena to Report Second Quarter 2026 Financial Results on August 6

July 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, AVTE, EIKN, and PRTA Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$14.71 -2.05 (-12.23%)

As of 09/23/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Eikon Therapeutics NASDAQ:EIKN

$7.94 -0.20 (-2.40%)

As of 10:27 AM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

OnKure Therapeutics NASDAQ:OKUR

$3.00 +0.06 (+1.90%)

As of 10:25 AM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Prothena NASDAQ:PRTA

$8.64 -0.04 (-0.47%)

As of 10:26 AM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OKUR, AVTE, EIKN, and PRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OKUR, AVTE, EIKN, and PRTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OKUR, AVTE, EIKN, and PRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, AVTE, EIKN, and PRTA Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Eikon Therapeutics NASDAQ:EIKN

OnKure Therapeutics NASDAQ:OKUR

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OKUR, AVTE, EIKN, and PRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OKUR, AVTE, EIKN, and PRTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OKUR, AVTE, EIKN, and PRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, AVTE, EIKN, and PRTA Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Eikon Therapeutics NASDAQ:EIKN

OnKure Therapeutics NASDAQ:OKUR

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools